111 related articles for article (PubMed ID: 12507541)
1. Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma.
Kil PJ; Goldschmidt HM; Wieggers BJ; Kariakine OB; Studer UE; Whelan P; Hetherington J; de Reijke TM; Hoekstra JW; Collette L
Eur Urol; 2003 Jan; 43(1):31-8. PubMed ID: 12507541
[TBL] [Abstract][Full Text] [Related]
2. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study.
Albrecht W; Collette L; Fava C; Kariakine OB; Whelan P; Studer UE; De Reijke TM; Kil PJ; Rea LA
Eur Urol; 2003 Nov; 44(5):505-11. PubMed ID: 14572746
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
4. Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy.
Theyer G; Dürer A; Theyer U; Haberl I; Ulsperger E; Baumgartner G; Hamilton G
Prostate; 1999 Oct; 41(2):71-7. PubMed ID: 10477903
[TBL] [Abstract][Full Text] [Related]
5. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
6. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Leibowitz RL; Tucker SJ
Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
[TBL] [Abstract][Full Text] [Related]
7. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
8. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
10. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299.
Eggener S
Urol Oncol; 2014 Aug; 32(6):936-7. PubMed ID: 25087673
[TBL] [Abstract][Full Text] [Related]
11. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr., University of Michigan, Division of Hematology/Oncology, 1500 E Medical Center Dr., 7314 CC, Ann Arbor, MI. N Engl J Med 2013;368(14):1314-25.
Trump DL
Urol Oncol; 2013 Nov; 31(8):1847. PubMed ID: 24210086
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
[TBL] [Abstract][Full Text] [Related]
13. Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal.
Kundranda MN; Muslimani A; Daw HA; Spiro TP
Clin Genitourin Cancer; 2007 Sep; 5(6):401-2. PubMed ID: 17956714
[TBL] [Abstract][Full Text] [Related]
14. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
15. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
[TBL] [Abstract][Full Text] [Related]
16. Intermittent complete androgen blockade in metastatic prostate cancer.
Rambeaud JJ
Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
[TBL] [Abstract][Full Text] [Related]
17. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
18. Serial tissue polypeptide specific antigen determination in the followup of hormone treated carcinoma of the prostate.
Kramer G; Steiner GE; Madersbacher S; Stulnig T; Lang T; Marberger M
J Urol; 1997 Oct; 158(4):1446-51. PubMed ID: 9302140
[TBL] [Abstract][Full Text] [Related]
19. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
20. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
